Why multi-company collaboration for HTA evidence generation in rare diseases is a good thing

Mar 22, 2019

Project HERCULES is a unique international multi-stakeholder collaborative project set up by Duchenne UK to develop tools and evidence to support Health Technology Assessment (HTA) and reimbursement decisions for new treatments for Duchenne Muscular Dystrophy (DMD). It brings together eight leading pharmaceutical companies, academics, patient organisations and advisers to develop and build a better evidence base for DMD to aid the pricing and reimbursement stage of drug development.

Source Health Economics are developing the core economic model for this collaboration. This is a rare and exciting prospect for several reasons.

Gold standard data

Typically, when core models are developed, the primary focus is the robustness of model methods, and the statistical techniques used to overcome the limitations of clinical trials, such as lack of a comparator, or limited study follow up. However, economic models are only as good as the data they use.

Data for natural history, health state utilities and resource use are often obtained via systematic literature and these data are not always available in rare diseases.

In Project Hercules, evidence is being generated for natural history, health-related quality of life, and resource use and costs by expert teams at the University of Leicester, ScHARR and HCD Economics respectively.

The team

The second key benefit of collaboration is the many experts involved – the sheer brain power, the specialist expertise, the many years of experience of multiple partners from patients and their families, academia, industry, consultancy and clinical practice. We benefit from the different perspectives, viewpoints and ideas; and if there is a stone left unturned at the end of this exercise, I would be very surprised.

The efficiency

As economists, we have to highlight the efficiencies of such collaboration. The generation of data requires investment of time and budget. The involvement of multiple manufacturers means this investment can be shared.

The collaboration has a project leadership team, sitting apart from the collaborating pharmaceutical partners that undertakes the extraordinary feat of orchestrating the partners, tasks, meetings and timelines of the project.

The input of the European Medicines Agency (EMA) and HTA bodies on our methods will be conducted just once with one core economic model and data set that will be used for multiple therapies and multiple HTA and reimbursement submissions.

Remembering why we do this

Lastly, but by no means least, Project Hercules meetings have never been just a group of industry and technical partners, discussing the relative merits of alternative model methods. The mothers of boys affected by DMD are part of the team, model health states were informed by patient experience.

This engagement was recognised by the EURORDIS Black Pearl Company Award for Patient Engagement.

For us, this keeps the reason we do what we do at the forefront of our minds. Ultimately, we are working for a future where effective, life improving, life changing therapies are brought to market for boys affected by DMD, their families and the remarkable mothers who brought this collaboration about.

More Insights

NICE RWE framework 

NICE RWE framework 

Previously, we discussed the use of real-world evidence (RWE) in the reimbursement assessment of medical devices. In this latest blog, we present an overview of the RWE framework created by the National Institute for Health and Care Excellence ... Read more

The 100,000 genomes project: paving the way for faster diagnosis and treatment of rare diseases

The 100,000 genomes project: paving the way for faster diagnosis and treatment of rare diseases

What are rare diseases?  In the  European Union, a rare disease is defined as a disorder affecting ≤5 in 10,000 persons  (1). Using this definition, the global population prevalence of rare diseases is estimated to be between 3.5–‍5.9% ... Read more

Use of RWE in the reimbursement assessment of medical devices

Use of RWE in the reimbursement assessment of medical devices

Hierarchy of evidence  Different study designs are often ranked in a hierarchy of evidence based on their validity and robustness. Randomised controlled trials (RCTs) are typically considered the gold standard source of evidence, ... Read more

The growing number of small interfering RNA-based therapies approved for reimbursement in the UK

The growing number of small interfering RNA-based therapies approved for reimbursement in the UK

The RNA interference pathway  Ribonucleic acid (RNA) is an important macromolecule in cells, involved in turning genetic information encoded by genes (made up of deoxyribonucleic acid ), into proteins needed by the cell. During the processes of ... Read more